---
schema_version: "secwatch.filing_event.v1"
accession: "0001472375-26-000133"
form_type: "8-K"
ticker: "RGPX"
cik: "0001357878"
company_name: "REGENEREX PHARMA, INC."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:34:33.742468+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Regenerex Pharma terminates CFO Kenneth Perry for cause; appoints Don E. Ray as interim CFO

## Summary
- Kenneth Perry placed on administrative suspension with pay on March 31, 2026.
- Board determined Perry's conduct constituted material breach and 'Cause' under employment agreement; termination effective May 2, 2026.
- Don E. Ray appointed Interim CFO effective April 1, 2026 for an initial 90-day term.
- CEO Greg Pilant recused himself from deliberations; independent board made decision.

## SEC filing metadata
- accession: 0001472375-26-000133
- form_type: 8-K
- ticker: RGPX
- cik: 0001357878
- company_name: REGENEREX PHARMA, INC.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357878/000147237526000133/0001472375-26-000133-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357878/000147237526000133/ixform8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001472375-26-000133
- JSON: https://secwatch.observer/filing/0001472375-26-000133.json
- Plain text: https://secwatch.observer/filing/0001472375-26-000133.txt

## Key facts
- Executive change
  Don E. Ray was appointed as Interim Chief Financial Officer at REGENEREX PHARMA, INC..
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: In connection with the foregoing, on April 1, 2026, the Board appointed Don E. Ray to serve as Interim Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1357878/000147237526000133/0001472375-26-000133-index.htm
- Executive change
  Kenneth Perry was terminated as Chief Financial Officer at REGENEREX PHARMA, INC..
  - Action: terminated
  - Role: Chief Financial Officer
  source text: Following the Committee’s review and recommendation, the Independent Board of Directors approved the termination of Mr. Perry’s employment for Cause, with notice of such termination delivered on May 2, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1357878/000147237526000133/0001472375-26-000133-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.